Beta emitter systems and results from clinical trials. state of the art.
Vascular brachytherapy has been established as the standard of care for the treatment of in-stent restenosis (ISR). Both beta and gamma emitters are currently in use for the prevention of ISR recurrence. The use of beta sources for vascular application is attractive from both the radiation exposure and safety points of view, and a wide variety of beta sources are available for this application. This review is intended to summarize the clinical trials utilizing beta emitter systems for the treatment of ISR and de novo lesions and their subsequent results.
Waksman
Ron
R
Washington Hospital Center, 110 Irving Street, NW, Suite 4B-1, Washington, DC 20010, USA. ron.waksman@medstar.net
Raizner
Albert
A
Popma
Jeffrey J
JJ
D001610:Beta Particles / Q000627:therapeutic use; D001918:Brachytherapy / Q000295:instrumentation*; D002986:Clinical Trials as Topic; D006083:Graft Occlusion, Vascular / Q000532:radiotherapy*; D006801:Humans